Table 1
Non-Autoinflammatory diseases(n=1545)Autoinflammatory diseases (n=117)
Age (years)
 Mean±SD54.7±17.538.7±20.5
 <1841/1545 (2.7)17/117 (14.5)
 18–54700/1545 (45.3)74/117 (63.2)
 55–64328/1545 (21.2)8/117 (6.8)
 65–74260/1545 (16.8)9/117 (7.7)
 ≥75216/1545 (14.0)9/117 (7.7)
 Female gender1038/1545 (67.2)64/117 (54.7)
Comorbidities
 Respiratory disease204/1543 (13.2)6/117 (5.1)
 Interstitial lung disease60/1543 (3.9)0/117 (0.0)
 COPD61/1543 (4.0)2/117 (1.7)
 Asthma95/1543 (6.2)4/117 (3.4)
 Cardiovascular disease177/1543 (11.5)11/117 (9.4)
 Coronary heart diseases146/1543 (9.5)9/117 (7.7)
 Stroke42/1543 (2.7)5/117 (4.3)
 Diabetes156/1543 (10.1)8/117 (6.8)
 BMI (kg/m²)26.0 (22.0 ; 29.0)23.0 (21.0 ; 26.0)
 <301054/1388 (75.9)98/111 (88.3)
 30–39.9297/1388 (21.4)10/111 (9.0)
 ≥4037/1388 (2.7)3/111 (2.7)
 Hypertension361/1543 (23.4)12/117 (10.3)
 Cancer57/1543 (3.7)3/117 (2.6)
 Smoking139/1543 (9.0)8/117 (6.8)
 Chronic renal failure80/1543 (5.2)5/117 (4.3)
Number comorbidities
 0674/1543 (43.7)76/117 (65.0)
 1466/1543 (30.2)26/117 (22.2)
 2230/1543 (14.9)8/117 (6.8)
 3103/1543 (6.7)4/117 (3.4)
 458/1543 (3.8)3/117 (2.6)
 >412/1543 (0.8)0/117 (0.0)
Rheumatic or inflammatory Diseases treatments
 Corticosteroid460/1542 (29.8)20/117 (17.1)
 Systemic corticosteroid doses≥10 mg/day176/458 (38.4)6/20 (30.0)
 NSSAIDs147/1542 (9.5)2/117 (1.7)
 Colchicine10/1542 (0.6)72/117 (61.5)
 Hydroxychloroquine146/1542 (9.5)0/117 (0.0)
 Methotrexate553/1542 (35.9)13/117 (11.1)
 Leflunomide66/1542 (4.3)0/117 (0.0)
 Salazopyrine17/1542 (1.1)0/117 (0.0)
 Mycophenolate Mofetil /mycophenolic acid41/1542 (2.7)0/117 (0.0)
 Azathioprine18/1542 (1.2)4/117 (3.4)
 IgIV10/1542 (0.6)0/117 (0.0)
Targeted biologic or synthetic therapies
 anti-TNF469/1542 (30.4)18/117 (15.4)
 anti-IL6R56/1542 (3.6)5/117 (4.3)
 anti-IL17A51/1542 (3.3)0/117 (0.0)
 anti-IL12/1542 (0.1)12/117 (10.3)
 abatacept34/1542 (2.2)1/117 (0.9)
 JAK inhibitor56/1542 (3.6)1/117 (0.9)
 Rituximab83/1542 (5.4)0/117 (0.0)
 Other biologics33/1542 (2.1)1/117 (0.9)
  • Values are presented as no./total no. (%) unless otherwise indicated

  • COPD, Chronic obstructive pneumopathy disease; IgIV, Intravenous immunoglobulins.